TABLE 2.
Drug Pharmacologya | Doses | Route | Strain/Species | Sex | ICSS Procedureb | Drug Effectc | Dependent Measure | Reference | ||
---|---|---|---|---|---|---|---|---|---|---|
Drug Name | Selectivity | Structure | Parameter | |||||||
mg/kg | ||||||||||
Cocaine | DA/NE/5HT | 0.63–10 | s.c. | Wistar rat | Male | Free operant | Facilitation | ↑rate | Wauquier and Niemergeers, 1974 | |
Cocaine | DA/NE/5HT | 1–10 | i.p. | Fischer rat | Male | Discrete trial | Amplitude | Facilitation | ↓CIT | Esposito et al., 1978 |
Cocaine | DA/NE/5HT | 1–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↑rate | Negus et al., 2012a |
Cocaine | DA/NE/5HT | 1.25–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↓θ0 | Tomasiewicz et al., 2008 |
Cocaine | DA/NE/5HT | 1–30 | i.p. | C57Bl6/J mouse | Male | Hybrid | Frequency | Facilitation | ↓θ0 | Fish et al., 2010 |
Cocaine | DA/NE/5HT | 1–30 | i.p. | DBA mouse | Male | Hybrid | Frequency | Facilitation | ↓θ0 | Fish et al., 2010 |
MDPV | DA/NE>5HT | 0.32–3.2 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↑rate | Bonano et al., 2014 |
MDPV | DA/NE>5HT | 0.1–2.0 | i.p. | Sprague-Dawley rat | Male | Discrete trial | Amplitude | Facilitation | ↓CIT | Watterson et al., 2014 |
GBR 12935 | DA>NE/5HT | 1.0–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↑rate | K. Freitas and S. S. Negus, unpublished |
RTI-113 | DA>NE/5HT | 0.32–3.2 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↑rate | Rosenberg et al., 2013 |
Methylphenidate | DA/NE>5HT | 0.1–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↑rate | K. Freitas and S. S. Negus, unpublished |
Buproprion | DA/NE>5HT | 3.2–32 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↑rate | Rosenberg et al., 2013 |
RTI-112 | DA/NE/5HT | 0.1–1.0 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↑rate | Rosenberg et al., 2013 |
Amitifadine | DA/NE/5HT | 1–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Mixed | ↑↓rate | L. L. Miller and S. S. Negus, unpublished |
Citalopram | DA/NE<5HT | 3.2–32 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Depression | ↓rate | Rosenberg et al., 2013 |
Clomipramine | DA<NE/5HT | 3.2–32 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Depression | ↓rate | Rosenberg et al., 2013 |
Fluoxetine | DA/NE<5HT | 1.0–10 | i.p. | Sprague-Dawley rat | Male | Free operant | Depression | ↓rate | Katz and Carroll, 1977 | |
Fluoxetine | DA/NE<5HT | 2.5-20 | i.p. | Wistar rat | Male | Discrete trial | Amplitude | Depression | ↑CIT | Lee and Kornetsky, 1998 |
Nisoxetine | DA/5HT<NE | 1–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Depression | ↓rate | Rosenberg et al., 2013 |
Nortryptaline | DA<5HT<NE | 1–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Depression | ↓rate | Rosenberg et al., 2013 |
Rate, response rate; CIT, current-intensity threshold; θ0, theta-0 threshold.
Selectivity for monoamine uptake inhibition.
First column indicates structure of experimental session (see text for details). Second column indicates stimulation parameter under manipulation across trials.
Most prominent drug effect on ICSS.